Broadwood Partners, L.P. - Jan 27, 2025 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role: Director, 10%+ Owner
Signature: Broadwood Partners, L.P., By: Broadwood Capital, Inc., By: /s/ Neal C. Bradsher, President
Stock symbol: LCTX
Transactions as of: Jan 27, 2025
Transactions value $: $6,000,000
Form type: 4
Date filed: 1/28/2025, 07:49 PM
Previous filing: Jan 16, 2025
Next filing: Feb 10, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LCTX	Common Shares	Purchase	$6M	+7.89M	+18.95%	$0.76	49.6M	Jan 27, 2025	Direct	F1, F2
transaction	LCTX	Common Shares	Purchase	$0	0	0%	$0.00^*	49.6M	Jan 27, 2025	See Footnote	F1
holding	LCTX	Common Shares						87.6K	Jan 27, 2025	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LCTX	Common Warrant	Purchase	$0	+7.89M		$0.00	7.89M	Jan 27, 2025	Common Shares	7.89M	$0.91	Direct	F1, F2, F4
transaction	LCTX	Common Warrant	Purchase	$0	0	0%	$0.00^*	7.89M	Jan 27, 2025	Common Shares	7.89M	$0.91	See Footnote	F1, F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners and Neal C. Bradsher as President of Broadwood Capital, Inc. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F2	On November 19, 2024, Broadwood Partners entered into a Securities Purchase Agreement with Lineage Cell Therapeutics, Inc. (the "Issuer") pursuant to which Broadwood Partners agreed to acquire (i) 7,894,737 of the Issuer's Common Shares, no par value (the "Common Shares") and (ii) 7,894,737 common share purchase warrants (the "Common Warrants"), each of which will be exercisable for one Common Share, from the Issuer in its registered direct offering for a total purchase price of $6,000,000, or $0.76 per Common Share and accompanying Common Warrant (the "Transaction"). The closing of the Transaction was subject to obtaining the approval of the Issuer's shareholders, which was obtained on January 27, 2025, and the closing of the Transaction occurred on the same date.
F3	These securities are owned by Neal C. Bradsher in his personal capacity.
F4	The Common Warrants will expire on the earlier of (a) May 21, 2028 and (b) the 90th day following the date of the public disclosure of the intent to advance OpRegen (also known as RG6501) into a multi-center phase 2 or 3 clinical trial which includes a control or comparator arm, or if the date of such public disclosure occurs prior to May 21, 2025, then the 90th day following May 21, 2025.